HaiChang Biotech Reports June Revenue of NT$14.7 Million, Up Over 200% Year-on-Year, Secures Thailand Class 4 Medical Device Approval

HaiChang Biotech (7814-TW) announced June revenue of NT$14.7 million, representing a 2.29-fold month-on-month increase and a 2.09-fold year-on-year surge. Cumulative revenue for the first half of the year reached NT$47.8 million, up 55.78% compared to the same period last year. The company attributes the growth to increasing sales volume of its core products and anticipates continued operational momentum.

The company has also made significant progress in expanding into ASEAN markets. It has received Thailand FDA approval for three key products—"HaiChang Collagen Regenerative Film," "HaiChang Collagen Bone Filler," and "HaiChang Collagen Matrix"—all designed for tissue regeneration and clinical wound repair. These products have now obtained Class 4 medical device marketing authorization, the highest classification in Thailand’s medical device regulatory system.

Securing Class 4 approval, the most stringent category, enables immediate commercialization in Thailand and is expected to translate into tangible export orders, directly boosting future revenue. The company emphasized that this regulatory milestone marks a critical step in its international strategy.

HaiChang Biotech is set to list on the GreTai Securities Market (TPEx) on July 15. CEO Hsin-Yu Ho stated, "Listing will allow us to access greater capital market resources and enhance corporate visibility. As our core regenerative medicine technologies gain wider clinical adoption, product shipments are entering an explosive growth phase. We will continue expanding overseas, and future operations look highly promising."